Carelink and Monsenso partner to deliver digitally enabled nationwide mental health services

Carelink and Monsenso partner to deliver digitally enabled nationwide mental health services

Carelink Nærhospital and Monsenso entered into a partnership and expect to deliver the first digitally supported mental health services in January 2024. 

Carelink Group, Denmark’s largest private health and welfare services group, and Monsenso, a leading provider of validated digital mental health solutions, have entered into a groundbreaking partnership that will redefine the way mental health services are delivered for the benefit of patients, healthcare professionals, and the healthcare sector as a whole.

Mental health is a crucial part of our society, and the need for innovative solutions to address challenges in this area has never been bigger. Carelink’s extensive experience in delivering high-quality healthcare services, combined with Monsenso’s advanced digital health solution, has the potential to create lasting value for both the healthcare sector, the work of healthcare professionals, and particularly for patients. The partnership aligns with the Danish government’s initiatives in psychiatry and the recently presented Finance Act for 2024.

Key points in this partnership include:

  1. Highly scalable digitally supported healthcare services: The partnership creates an innovative foundation that integrates traditional mental health services with advanced digital solutions. This comprehensive offering will provide individual users with tools for digital self-help, self-monitoring and effective remote clinician follow-up before, during, and after treatment.
  2. Addressing workforce issues: The shortage of qualified personnel in mental health is a challenge. This partnership aims to alleviate the problem by optimising resources and leveraging technology to expand the reach of healthcare professionals, enabling them to serve a larger number of patients.
  3. Reduced waiting times: Long waiting lists for mental health services are a significant problem nationwide. The collaboration will streamline the process and offer timely assistance through a combination of digital solutions and remote follow-up, ensuring that patients receive the support they need promptly.
  4. Improved patient experience: Patients will experience a more patient-centered and convenient approach to assessment and treatment for mental disorders. The partnership will enhance the patient experience, promote patient involvement, and provide effective follow-up, support, and treatment.
  5. Quality treatment: The combined offering will promote better treatment outcomes, as patients will have the necessary tools and support for digital self-help, self-monitoring, and effective remote follow-up. This is expected to lead to improved quality of life, more efficient processes, and a reduction in relapses.

“We have entered into this partnership to meet the pressure on psychiatry and the healthcare sector today. We aim to create a Digital First but not Digital Only offering, making waiting lists, assessment, and treatment processes more patient-centric. We believe we can achieve this by leveraging the latest clinically validated technologies to effectively follow up on treatment – also at a distance and in patients’ own homes,” says Maria Pico Almsgaard, CEO of Carelink Nærhospital.

“The potential in the partnership to create easily accessible, nationwide offerings is significant. Far too many patients are waiting for treatment and not provided with the effective, digitally supported offerings that they would like. Better assistance for children and young people, as well as digital offerings, is a priority for the government, and that’s why we have also started with digitally supported offerings for children and young people, but with new pathways continuously added,” says Thomas Lethenborg, CEO of Monsenso.

Click the button below for more information about the Monsenso solution.

Monsenso signs new agreement with a leading pharmaceutical for a real-world data project in Denmark

Monsenso signs new agreement with a leading pharmaceutical for a real-world data project in Denmark

Monsenso signs a new agreement with a leading pharmaceutical company to implement its solution for decentralised patient-centric real-world data collection in a chronic disease area.

Under the new agreement, Monsenso will deliver and support real-world patient data collection for a decentralised patient-centric study expected to take place over the next 12 months.

The agreement and the solution delivered build on Monsenso’s existing platform, which will be customised to support the specific study and the disease of the patient group. It also includes developing new features to support the patient-centric real-world data study, which will position Monsenso’s solution even stronger in the future.

“With this project, we hope to contribute to getting deeper learnings on which treatments work for which patients by continuously engaging and collecting real-world data from patients.

The potential of this engagement is significant – both with the pharmaceutical company itself across other geographies and disease areas as well as with similar companies.” says Thomas Lethenborg, CEO of Monsenso.

The project comes one year into the start of the PhaseV research project, where Monsenso further develops its solution to fully support decentralised real-world data studies and trials in collaboration with leading pharmaceutical companies and research institutions.

Click the button below for more information about the Monsenso solution.

Monsenso app used for research project promoting psychological resilience and nature connectedness in university students

Monsenso app used for research project promoting psychological resilience and nature connectedness in university students

The two-day Autumn School event with GoGreenRoutes hosted at the Hamilton Institute, Maynooth University (October 12th – 13th), saw the launch of a new configuration of our mobile application designed to promote psychological resilience and nature connectedness in university students across six participating European cities. Both mental health and nature are currently under threat globally, yet the optimal solution may be to address both challenges together with benefits for well-being and the natural environment.

The six-week digital programme focuses upon cultivating key psychological skills and enhancing participants’ relationship with the natural world through engagement with bespoke psychoeducational materials and a suite of nature-based activities. The programme will be made available to a range of students in GoGreenRoutes ‘Cultivating’ Cities, Limerick, Lahti, Umeå, Tallinn, Versailles and Burgas, over the coming six-month period.

The programme development has been led by the Institute of Child Education and Psychology, Europe (Ireland) and Monsenso (Denmark), and this process has been carefully conducted with the end user in mind. Programme content is based upon cutting-edge research in the promotion of psychological resilience and the need to cultivate the relationship between humans and nature.

Participating users of the research project will consist of university students in each of the six cities, who will embark upon an experiential six-week learning journey wherein one specific domain of psychological resilience will be addressed each week. A selection of five suggested nature-centered activities is provided in the application for each of the six resilience domains, with users retaining a sense of autonomy as to determining which of the activities are most suitable to their needs and preferences.

Participant engagement with the programme will be monitored on an ongoing weekly basis, and the efficacy of the programme will be assessed based upon the impact noted in users’ psychological resilience, nature connectedness, psychological wellbeing, pro-environmental attitudes and behaviours, sleep quality, and levels of outdoor activity across the six-week engagement period.

The first rollout of the programme will commence in mid-November and the implementation process will continue in the six European cities until April 2024.

For more information about the research project, visit GoGreenRoutes.eu.

Monsenso signs major new agreement with a European capital

Monsenso signs major new agreement with a European capital

Monsenso has been elected the best bidder in a public tender and signs a framework agreement to deliver its digital solution to support health services in a European capital.

The framework agreement makes it possible for the city, the university, a hospital and other health institutions in the area to purchase Monsenso’s validated digital health solution and associated services for 30 months with the possibility to prolong for two times five years.

The signing of the framework agreement comes with initial million-kroner orders to implement and operate Monsenso’s solution for 30 months to digitally support and increase access to services for young people with mental health challenges and for people with addiction.

Service users are provided with an app, which is used to collect real-time patient-reported information and to give self-help information and guidance between consultations. Health professionals gain access to a clinical web portal to follow their patients remotely and gain valuable information about behaviour, symptoms and adherence to treatment. This enables clinicians to provide a data-driven treatment and allows for proactive follow-up. In addition, the solution supports communication between service users and therapists.

The potential of this framework agreement is significant. It comes with an initial order that will generate recurring revenue for Monsenso in the coming years, and the potential from other departments and entities within the city already covered by the framework agreement as well as similar European cities is substantial” says Thomas Lethenborg, CEO of Monsenso. “Addiction and youth mental illness are both large burdens of disease and affect far too many people, so we are proud to contribute to providing better access to high-quality services in the city”.

Further information:

Monsenso:

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

This is a shortcut to read more about the solution.
Monsenso participates in MENTBEST – a European community-based and personalised digital intervention project

Monsenso participates in MENTBEST – a European community-based and personalised digital intervention project

The new European intervention project MENTBEST will deliver an innovative and comprehensive community-based intervention programme and a personalised digital application based on Monsenso’s solution to prevent and mitigate the mental health challenges associated with dramatic and rapid change in Europe. 

European societies are severely impacted by global trends such as war, economic crisis, climate changes, migration, pandemics, and ageing population. These megatrends can negatively affect people’s psychological health and wellbeing – with vulnerable groups being at particular risk. Thus scalable intervention programmes are needed to build resilience and enhance self-help competency to prevent mental illness.

Therefore, the European Union is funding the design and delivery of validated community-based interventions and innovative technologies to empower individuals from vulnerable groups to better manage mental health challenges associated with dramatic and rapid change in Europe. During the MENTBEST project, interventions will be delivered to communities in five different countries, namely Albania, Estonia, Greece, Ireland, and Spain. The project is led by the European Alliance Against Depression, and includes a consortium of 14 European partners with an extensive range of expertise. 

As part of the intervention project, an AI-enabled app based on Monsenso’s digital health platform will be developed and trialed to help prevent mental illness among high-risk groups, particularly migrants/refugees, older people, younger people, long-term unemployed, and those already struggling with their mental health. The goal of the AI-enabled personalised self-care program is to allow vulnerable people to use their long-term smartphone-generated data to support their mental health self-management. 

“The ambition of MENTBEST is to increase resilience and self-help competencies of people most often left behind in times of rapid and dramatic societal changes.”, explains Professor Ulrich Hegerl, MENTBEST Project Coordinator and President of the European Alliance Against Depression.

“Timely access to evidence-based support has the potential to empower vulnerable people to reduce the risk of developing mental illnesses. We are looking forward to participating in MENTBEST and expanding our platform to provide personalised, AI-driven self-care programs to people at high risk of facing difficulties with their mental health.”, says Thomas Lethenborg, CEO at Monsenso. 

The MENTBEST app will be trialed in Denmark, Germany, and Spain under the leadership of Professor Lars Kessing and Associate Professor Maria Faurholt-Jepsen from Mental Health Services of the Capital Region of Denmark.

“The project builds on our year-long research experience with digital mental health for more severe mental health illnesses. We see great potential in digital, data-driven mental health also for mild to moderate conditions and consequently look forward to driving the digital intervention part of the MENTBEST project with Monsenso”, says Maria Faurholt-Jepsen, Associate professor at Mental Health Services in the Capital Region of Denmark.

Facts
Project title: MENTBEST
Total budget: DKK 52.1 mio.
Net contribution to Monsenso: DKK 5.7 mio.
Duration: 5 years

About the partners
The project is led by the European Alliance Against Depression. The consortium entails leading experts in mental health promotion, resilience, wellbeing and primary prevention of disorders, mental disorders and suicide prevention, mental health in the workplace, mental health in children and adolescents, mental health in old age and experts in e-mental health and support technology, public policy, public education and evaluation. The consortium members are European Alliance Against Depression Ev, Instituto de Saúde Pública da Universidade do Porto (Portugal), Universidad Autónoma de Madrid (Spain), National Suicide Research Foundation (Ireland), Region Hovedstaden (Denmark), Det Nationale Forskningscenter for Arbejdsmiljø (Denmark), Eesti-Rootsi Vaimse Tervise ja Suitsidoloogia Instituut (Estonia), Stiftung Deutsche Depressionshilfe Und Suizidpraevention (Germany), Qendres Se Shendetit Dhe Mireqenies Komunitare (Albania), Katholieke Universiteit Leuven (Belgium), Pintail Ltd (Ireland), Kentro Erevnon Notioanatolikis Evropis Astiki Mi Kerdoskopiki Etaireia (Greece), and Fundacio Institut Hospital del Mar D’Investigacions Mèdiques (Spain).

Further information:
Monsenso:
CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Certified Adviser:
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk

Artificial intelligence creates individually tailored treatment for depression

Artificial intelligence creates individually tailored treatment for depression

A new innovation project “Personae” will provide easier access to personalised digital treatment for patients with depression through Monsenso’s digital health platform. The project leverages patient-reported outcomes and AI to screen patients and to deliver a treatment tailored to the individual patients’ needs.

According to the WHO, more than one billion people worldwide have mental disorders, but the number of individuals receiving help is alarmingly low. In Western Europe, for instance, only half of the citizens with anxiety or depression receive relevant treatment. At the same time, the healthcare system is challenged by a shortage of healthcare professionals.

Therefore, Innovation Fund Denmark is funding the development of a personalised treatment based on Monsenso’s digital health solution, which will leverage artificial intelligence to tailor the treatment to the individual patient’s needs.

Today, digital programs provide evidence-based treatment to citizens with depression, for example in the Danish clinic” Internetpsykiatrien”. Research shows that such programs have the same effect on citizens with mild to moderate depression as physical therapy sessions. The potential is huge, with thousands of citizens on waiting lists or receiving no relevant support at all. However, delivering a personalised intervention to everyone is challenging. Some patients benefit from a fully automated, digital treatment program, others need their treatment program supported by a psychologist, and yet other patients with complex life situations need physical meetings with their healthcare providers.

“The project enables us to use artificial intelligence, which, in collaboration with Monsenso’s digital health solution and the Internetpsykiatrien, can ensure that more people can quickly get access to the right treatment. This next generation of digital treatment will make it much easier to offer a fully or partially digital treatment that matches each individual’s needs,” says Kim Mathiasen, research director at the Center for Digital Psychiatry, who leads the Personae project.

”We see great potential in this project. It enables us to continue the development of our digital health solution and further validate it. It will improve the way we use people’s own health and behavioral data to keep them engaged, customise their treatment and support clinical decision-making at scale”, says Thomas Lethenborg, CEO at Monsenso.

”The unique, patient-reported data that will be generated from the screening and continuous use of Monsenso’s solution in Internetpsykiatrien is a fantastic foundation for development, training and validation of algorithms for automatisation of decision support and optimisation of treatment pathways”, says Dr. Pepijn Van de Ven, Senior Lecturer at Limerick University.

The primary ambition of the project is to develop intelligent adaptations of treatment content to match patients’ symptoms and life situations. The solution should be able to identify early signs of drop-out and support patients’ and healthcare providers’ decisions concerning treatment. The artificial intelligence solutions will be incorporated into both the public Internetpsykiatrien clinic, which the Center for Digital Psychiatry operates, and into the digital health solution of Monsenso.

The project is led by the Center for Digital Psychiatry, which, in Danish and international contexts, is a pioneer in internet-based therapy in terms of development, research, and operation. This project combines their research and extensive clinical experience with the competencies and commercial platform of Monsenso, as well as the unique competencies in artificial intelligence for mental health at the University of Limerick. 

Facts
Project title: Personae – Personalised Digital Treatment of Depression
Total budget: DKK 22.1 mio.
Innovation Fund Denmark investment: DKK 16.5 mio.
Net contribution to Monsenso: DKK 3.9 mio.
Duration: 4 years

About the partners
Center for Digital Psychiatry at Region Southern Denmark works to ensure that all Danes have easy and equal access to mental health. In a Danish and international context, the Center for Digital Psychiatry are frontrunners in the use of digital solutions for mental health promotion and psychiatric treatment and they are experts in matching the current needs of psychiatry with the right digital technology.

The University of Limerick, Department of Electronic & Computer Engineering, has high expertise in research and teaching in information and communication technology. The Department of Electronic & Computer Engineering is a leader in research on artificial intelligence for Internet-based therapy.

Odense University Hospital, the Danish Depression Association and the strategic innovation agency Is It a Bird are also involved in the project.

Further information:
Monsenso:
CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Certified Adviser:
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk